Date Time
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”
WHO validates China s Sinopharm Covid vaccine for emergency use
By IANS |
Published on
Fri, May 7 2021 22:57 IST |
4 Views
WHO validates China s Sinopharm Covid vaccine for emergency use. Image Source: IANS News
Geneva, May 7 : The World Health Organization (WHO) on Friday approved the Covid-19 vaccine developed by China s Sinopharm for emergency use.
The move paves the way for the Sinopharm vaccine to be rolled out globally. This afternoon, the WHO gave emergency use listing to Sinopharm, Beijing s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, WHO Director-General Tedros Ghebreyesus said during a webinar on Covid-19.
WHO approves Chinese COVID-19 vaccine for emergency use
United Nations
08 May 2021, 07:21 GMT+10
A COVID-19 vaccine produced in China has been given the green light for global rollout, potentially paving the way for its use in underserved countries, the World Health Organization (WHO) announced on Friday.
The UN agency has approved the Sinopharm vaccine for emergency use, which is a prerequisite for inclusion in the global vaccine solidarity initiative, COVAX.
The vaccine is easy to store, making it suitable for locations with limited resources, and proved 79 per cent effective in clinical trials. The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk , said Dr Mariângela Simao, WHO Assistant-Director General for Access to Health Products.
COVID-19: WHO approves emergency use of China s Sinopharm COVID-19 vaccine ANI | Updated: May 08, 2021 02:41 IST
Geneva [Switzerland], May 8 (ANI): The World Health Organisation (WHO) on Friday approved the Chinese SinopharmCOVID-19 vaccine for emergency use, paving the way for it to be rolled out globally.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariangela Simao, WHO Assistant-Director General for Access to Health Products, in a statement.
Advertisement
“In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility. The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker on the vaccine vials that change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
“WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalised disease was estimated to be 79%, all age groups combined.